Trial Profile
Effects of Prescription OMega-3 Fatty Acids (Omacor, Lovaza) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications Coronary artery disease; Hypertriglyceridaemia
- Focus Pharmacodynamics
- Acronyms OMPA-CAD
- 01 Jul 2011 Status changed from not yet recruiting to completed
- 01 Jul 2011 EudraCT2009-018211-71 added as identifier
- 01 Jul 2011 Results published in the Cardiology.